Brodalumab, a monoclonal antibody binding to IL-17 receptor A and blocking IL-17A, IL-17C, IL-17F, IL-17A/F, and IL-17E (also known as IL-25), got the FDA approval for adult psoriasis in 2017 [18]. Here, IL17A is linked to psoriasis.